Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of Xeloda with radiotherapy in locally advanced rectal cancer
2008-003980-38Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in rectal cancer, sponsored by Roche. Primary endpoint: Pathological complete response rate. Started Jul 2008; status: completed.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2008-003980-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003980-38.